SG
TECX

StoneX Group’s Tectonic Therapeutic TECX Stock Holding History

StoneX Group’s Portfolio TECX Stock Details TECX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,250
Closed -$13.8K – 535
2022
Q2 		$13.8K Buy
+1,250
New +$14.7K ﹤0.01% 448

Other funds holding TECX

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

StoneX Group's TECX Position: Q3 2022 in Review

StoneX Group sold out of Tectonic Therapeutic (TECX) in Q3 2022, closing a stake of 1,250 shares — an estimated $13.8K sold.

StoneX Group first reported a position in TECX in Q2 2022 and held it in 1 quarter. The position peaked at $13.8K in Q2 2022. 54 funds tracked by Wall St. Rank hold TECX as of Q3 2022.

  • StoneX Group reported no remaining Tectonic Therapeutic position as of Q3 2022 after selling out during the quarter.
  • StoneX Group sold 1,250 Tectonic Therapeutic shares in Q3 2022, an estimated $13.8K.
  • StoneX Group first reported a position in Tectonic Therapeutic in Q2 2022 and held it in 1 quarter.
  • StoneX Group's Tectonic Therapeutic position peaked at $13.8K in Q2 2022.
  • 54 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q3 2022.

Based on StoneX Group's 13F filing for Q3 2022, filed 8 Nov 2022.